Literature DB >> 15051383

Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V.

Prem L Sharma1, Viktoria Nurpeisov, Kimberly Lee, Sara Skaggs, Christina Amat Di San Filippo, Raymond F Schinazi.   

Abstract

Understanding of the mechanisms of interaction among nucleoside reverse transcriptase inhibitor (NRTI)-selected mutations in the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) coding sequence is essential for the design of newer drugs and for enhancing our vision of the structure function relationship among amino acids of the polymerase domain of HIV-1. Although several nucleoside reverse transcriptase inhibitors select RT mutations K65R and L74V, the combination of 65R + 74V is rare in clinics. A novel NRTI (-)-beta-d-dioxolane-guanosine (DXG) is known to select in vitro either the 65R or 74V mutant virus. These mutations were not selected together during repeated passaging of the HIV-1 in the presence of this drug. To analyze the impact of these RT mutations on viral replication, a double mutant containing K65R + L74V was created by site-directed mutagenesis in a pNL4-3 background. Replication kinetic assays revealed that the mutant K65R + L74V is unstable, and 65R-->K reversion occurs during replication of virus in phytohemagglutinin (PHA)-stimulated human peripheral blood mononuclear (PBM) cells in the absence of selection pressure. Replication kinetic assays in MT-2 cells demonstrated that double mutant 65R + 74V is highly attenuated for replication and the initiation of reversion is related to the increase in RT activity. Additionally, the suppression of viral replication in the presence of DXG or under suboptimal human recombinant interleukin-2 leads to minimal or no 65R-->K reversion. These observations provide evidence that 65R-->K reversion in the double mutant 65R + 74V is dependent on a specific rate of viral replication in a pNL4-3 background. A similar phenomenon may occur in vivo, which may have implications for treatment management strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15051383     DOI: 10.1016/j.virol.2003.11.013

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Replication-independent expression of anti-apoptosis marker genes in human peripheral blood mononuclear cells infected with the wild-type HIV-1 and reverse transcriptase variants.

Authors:  Prem L Sharma; Himabindu Chunduri; Jasen Wise; Rondeen Mindley; David Rimland
Journal:  Viral Immunol       Date:  2012-01-12       Impact factor: 2.257

Review 3.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Authors:  Kalyan Das; Eddy Arnold
Journal:  Curr Opin Virol       Date:  2013-04-19       Impact factor: 7.090

Review 4.  Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Authors:  Carlo Giaquinto; Osvalda Rampon; Martina Penazzato; Federica Fregonese; Anita De Rossi; Ruggiero D'Elia
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 5.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

6.  Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.

Authors:  Prem L Sharma; James H Nettles; Anya Feldman; Kimberly Rapp; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2009-06-23       Impact factor: 5.970

7.  A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.

Authors:  Himabindu Chunduri; David Rimland; Viktoria Nurpeisov; Clyde S Crumpacker; Prem L Sharma
Journal:  Virol J       Date:  2011-01-21       Impact factor: 4.099

8.  Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.

Authors:  Kalyan Das; Rajiv P Bandwar; Kirsten L White; Joy Y Feng; Stefan G Sarafianos; Steven Tuske; Xiongying Tu; Arthur D Clark; Paul L Boyer; Xiaorong Hou; Barbara L Gaffney; Roger A Jones; Michael D Miller; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

9.  Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.

Authors:  Giovanni Villa; Richard O Phillips; Colette Smith; Alexander J Stockdale; Alessandra Ruggiero; Apostolos Beloukas; Lambert T Appiah; David Chadwick; Fred S Sarfo; Anna Maria Geretti
Journal:  J Antimicrob Chemother       Date:  2018-11-01       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.